In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary ...

Cold air can irritate the airways that carry air into the lungs, potentially causing symptoms like coughing, chest tightness, and trouble breathing.

Drugmaker Cipla has launched Afrezza (insulin human) inhalation powder, the company said, about a year after the product got ...

Peak season ranges from late December to mid-February every year, the CDC website says. Last year in North Carolina, RSV ...

Cipla has launched Afrezza, an inhaled insulin powder, offering a needle-free alternative to traditional injectable insulin therapy for diabetes patients.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...

Oral corticosteroids present significant long-term risks with uncertain evidence for improving asthma outcomes, according to data presented at the American College of Allergy, Asthma & Immunology ...

Paris: Sanofi and Regeneron have announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet ...